APAC's non-small cell lung cancer market to hit $4.9 billion by 2022, report predicts

6 May 2016

The non-small cell lung cancer (NSCLC) market in Asia-Pacific (APAC) countries will experience strong growth from $2.7 billion in 2015 to $4.9 billion by 2022, a compound annual growth rate of 8.7%, according to GBI Research.

APAC countries are in a hugely-populated region that includes India, China, Australia, South Korea, and Japan.

The latest report of GBI Research, a business intelligence provider, predicts that particularly important drivers of growth include immune-checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), which are marketed by US pharma giants Bristol-Myers Squibb (NYSE: BMY) and Merck & Co (NYSE: MRK), respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK